Our own William Roth Roth weighs in on the state of the generics industry and the Medicare Drug Shortage Prevention and Mitigation Program proposed legislation in Pharmacy Practice News Read his hot take: https://bit.ly/4eRSulB
IntegriChain
Pharmaceutical Manufacturing
Philadelphia, PA 73,847 followers
Data-Driven Commercialization
About us
IntegriChain helps Pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. We are doing this by building Pharma’s data-driven commercialization platform – from strategy to operational execution. Our unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net. We are backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Pharma.
- Website
-
https://www.integrichain.com
External link for IntegriChain
- Industry
- Pharmaceutical Manufacturing
- Company size
- 501-1,000 employees
- Headquarters
- Philadelphia, PA
- Type
- Privately Held
- Founded
- 2005
- Specialties
- Life Sciences Channel Data and Analytics, Pharmaceutical Commercial Data Analytics, Business Intelligence, Advanced Analytics, Distribution Analytics, Patient Access, Market Access, Specialty Pharmaceuticals Analytics, Payer Analytics, Access Management, Government Pricing, Rebate Processing, Patient Services, Channel Data Aggregation, Inventory Analytics, Pharma Access, Pharma Distribution, Pharma Distribution Management, Master Data Management, Data Science, and Gross to net automation
Products
IntegriChain ICyte Platform
Pharmacy Management Systems
IntegriChain helps Pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. We are doing this by building Pharma’s data-driven commercialization platform – from strategy to operational execution. Our unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net.
Locations
-
Primary
8 Penn Center
1628 JFK Boulevard
Philadelphia, PA 19103, US
-
201 S Maple St
Ambler, Pennsylvania 19002, US
-
Pancard Club Rd
M Agile, Samarth Colony
Baner Pune, Maharashtra 411045, IN
Employees at IntegriChain
-
Gary Palgon, CISSP
Sales. Marketing and Operations Executive; Healthcare/Life Sciences; Analytics/Security/Cloud
-
Michael Kerman
Marketing and Technology Executive | Revenue Generator | Talent Developer
-
David Weiss
-
Vickie Kozhushchenko
CHRO, delivering HR Strategy, Peer & Leadership Coaching, Org Dynamics and Transformation. I bring strategic HR thinking to private equity-backed…
Updates
-
Before the holiday weekend, check out the latest Industry Insights from Jennifer Sharpe, MBA, Jui Andhare, MBA and Jyoti Dubey here: https://bit.ly/4bsYsWW
-
Branded pharmaceutical manufacturers from large to emerging are struggling to ensure patients can find pharmacies that are capable and willing of dispensing Gen Med non-specialty brands, which account for 8% of the prescriptions that flow out of the pharmacy. Home delivery and digital pharmacy have attempted to provide feasible solutions, but to date have been insufficient to address these mounting barriers to access. Join Daniel Landis and Katie Herrick from Blue Fin Group, an IntegriChain Company as they discuss these challenges in Part 1 of our 3 part webinar series on Optimizing Physical Access and Affordability Challenges for Branded Rx Products - Meeting a $35 Patient Out-of-Pocket Target. Register today. https://bit.ly/3W5tzn1
-
We are thrilled to announce the promotion of Jeffrey Baab to Partner on our Advisory Services team. Jeff is a trusted advisor to so many Pharma companies, guiding them through the latest legislative requirements, walking them through pricing and contracting scenarios, and helping them optimize their net revenue and patient access. He is also a trusted leader on our broader Consulting team and a popular frequent speaker at industry events. Congratulations, Jeff, on your well-deserved promotion!
-
Since the IRA went into effect in August 2022, manufacturers have struggled to understand exactly how the significant Part D benefit redesign and the resulting shift in expenditure between CMS, payers, manufacturers, and patients would impact manufacturer liability, payer coverage decisions, and contract negotiations. Here are 5 things you should be thinking about regarding Part D redesign and the upcoming 2026 bid cycle: 1) Payer economics of individual brands may vary based upon phase in eligibility 2) Dynamics within LIS and non-LIS require careful evaluation 3) Consider your multi-year bid strategy as phase in schedule changes yearly through 2031 4) Rebate dollars will become more valuable as payers are expected to retain a higher percentage of DIR in the years ahead 5) CMS’ expenditures in catastrophic coverage will decline but their direct subsidies to plan are expected to increase substantially Learn More: https://lnkd.in/dUiREnQW
-
Join IntegriChain and Blue Fin Group, an IntegriChain Company at the Access Insights Conference from October 14-16 at the Mayflower Hotel. Gain insights on strategies, tactics,and benchmarks. Reserve your spot today: https://lnkd.in/eYB8irsw
-
We are thrilled to announce that we’ve acquired BridgeView Data Solutions. Combined, we bring best-in-class data aggregation and integrated CDW offerings to the Pharma industry. We want to welcome Michael Zubey Sankalp Shrivastava and the entire Bridgeview Data Solutions team to our umbrella. We’re excited to join forces and accelerate our innovation! read more here: https://bit.ly/3VxLT6K
-
Meet our leaders: CEO Joshua Halpern Halpern leads our dedicated customer-centric team that helps Pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. Technology + Data + Consulting + Outsourcing is the answer. Learn more here: https://lnkd.in/eaiXAMJ
-
IntegriChain reposted this
Get ahead of the curve! This month's IntegriChain Industry Insights features expert updates from Nick Iaconi, Carter H., and Jui Andhare, MBA. Explore their insights here: hhttps://lnkd.in/dYiNDuS8
-
The early bird discount for our Access Insights Conference ends June 18th. No matter the type of therapy you are bringing to market, we'll provide the latest data-driven commercialization strategies, tactics, insights, and benchmarks from October 14 - 16 at the Mayflower Hotel. Don't miss out and register today: https://lnkd.in/eYB8irsw